Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival?
A review of 50 patients treated with strontium-89 for prostate cancer bone metastases from January 1993-1997 at the Wellington Cancer Centre was undertaken to determine if there was any correlation between changes in prostate-specific antigen (PSA) following treatment and subsequent survival. Thirty cases were evaluable for PSA response. Of these, 14 had a fall in PSA following strontium-89 treatment, and their mean survival was 641 days. The remaining 16 patients did not demonstrate a post-treatment fall in PSA and their mean survival was 275 days. A difference between these two groups in the time to development of new bone symptoms following treatment was also observed. No significant correlation between pretreatment PSA and PSA response was observed. In conclusion, a PSA response following strontium-89 treatment appears to predict for improved survival in patients with bone metastases from carcinoma of the prostate. Further prospective studies are indicated.
Zyskowski
A
A
Wellington Cancer Centre, Wellington Hospital, Private Bag 7902, Wellington, New Zealand. a.zyskowski@wnhealth.co.nz
Lamb
D
D
Morum
P
P
Hamilton
D
D
Johnson
C
C
D000368:Aged; D001859:Bone Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000473:pathology*; D012189:Retrospective Studies; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
D013326:Strontium Radioisotopes; D017430:Prostate-Specific Antigen